about
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.How I manage priapism in chronic myeloid leukaemia patients.EZH2 in normal and malignant hematopoiesis.The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsTargeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.Evolving molecular therapy for chronic myeloid leukaemia--are we on target?Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cellsAutocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.Chronic myelogenous leukemia stem cells: What's new?Targeting hedgehog in hematologic malignancy.Targeting chronic myeloid leukemia stem cells.Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.The role of the bone morphogenetic proteins in leukaemic stem cell persistence.Hedgehog signaling in cancer stem cells: a focus on hematological cancers.Novel drug therapies in myeloid leukemia.DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AMLA 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cellsBCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells.Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation.Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors.Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.Cancer stem cell definitions and terminology: the devil is in the details.Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progressionChronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylationHypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approachPoor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infectionThe use of a risk group stratification in the management of invasive fungal infection: a prospective validationCorrection: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
P50
Q28294205-8AA044F5-CF02-4BA1-9988-3499BDA356A7Q34031890-E28E035B-C4A4-493F-BB43-855B963C7130Q34375614-3F1C3C04-DFAB-4579-BA31-09862693F2C6Q34806728-CDCC7B12-42DF-45EF-BE94-E7CC64802591Q36030919-C219379F-9570-49EF-ADA7-34E2EB258A4BQ36276288-2388123A-FDA8-478B-82F9-353956EDA9E2Q37362983-C2CD77C5-FA3B-40A1-A006-BB423E8963F6Q37450433-28B4B9D5-F786-40C8-BCD2-1123D34F0270Q37635609-61D2B68B-732E-495D-95F8-65E20381287EQ37738569-5083B562-B9A0-4598-9F00-F3A51912E020Q37973718-9E19EED3-1AA4-4142-915F-2B379BB8BED2Q38069545-57933EE8-801C-4663-BBBC-40F0393E43DEQ38076368-CA85BD56-061D-4E1B-AE0E-BA0072E40052Q38238611-CB7CED70-E618-4BFB-A50E-1D38928FE640Q38359705-2009561A-4FF0-479A-8935-07D7217E6822Q38510486-86B353BF-260D-468E-8A64-69044C5B0012Q38947913-6650837F-D3F5-4176-A938-A0AA80682919Q39017947-0218ED69-7CD7-42BA-A8A1-F755E23AA70BQ39560403-51284583-F7DD-46A2-9D7D-BB677ACF2139Q40298317-F7B0F730-F2F3-4C22-B1D6-C3FE4F9205BFQ43279503-EEC1686B-E172-42C2-AF19-38838738DD60Q43286629-3F93827C-DAE3-4F00-BC1D-74030ED9185EQ43746814-3A1A94C4-4785-4F01-BF81-62CB4F2C5CD0Q44216036-3A2A4022-7F87-4FA9-8568-9BCA220AEB11Q44571503-77DE31A6-010D-4D49-8909-8AD1096B2938Q45148328-ED16DF07-AEC6-4A0A-B0FD-35A9C35374D3Q46006972-9E72FEF7-01F7-4B17-A65A-75B0E5E66FAAQ46672455-049BF242-4125-49DE-B655-E66A066C36B5Q46835097-D5FC5A6D-5311-478D-ADDB-6EB5A2F4C8A4Q46905301-70544F75-6A16-4A69-9B57-0F8ACB3E1019Q46937459-498DC6D0-448F-4958-8BB4-704C485E83AAQ51541983-2E606BEF-EA3A-41C8-A71E-F1FCCF0FDC53Q53140630-083341F7-629E-4159-9A9E-30EFA79D420EQ54470011-E33C3F42-7351-4A69-9846-545907143E3EQ61776046-3815ABF5-2973-472D-BEEB-23D46A0770E1Q61872970-AE0F9884-D360-4D66-AE01-07392D969860Q61872982-F0148D51-C160-43C8-BD42-C91EB5C9F84EQ61872989-66271F8D-DD8B-44F7-8B16-0F5EC500FB34Q61872992-7AB18078-95CE-4AD3-B9CE-D25F86D992BAQ89475193-2D869498-1D12-4357-9DCF-60F7E5112E52
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mhairi Copland
@ast
Mhairi Copland
@en
Mhairi Copland
@es
Mhairi Copland
@nl
Mhairi Copland
@sl
type
label
Mhairi Copland
@ast
Mhairi Copland
@en
Mhairi Copland
@es
Mhairi Copland
@nl
Mhairi Copland
@sl
prefLabel
Mhairi Copland
@ast
Mhairi Copland
@en
Mhairi Copland
@es
Mhairi Copland
@nl
Mhairi Copland
@sl
P108
P106
P21
P31
P496
0000-0002-7655-016X
P569
2000-01-01T00:00:00Z